Novartis, India Clash Over Patent Laws

By Vinayak on Tuesday, September 10, 2013 with 1 comment

Latest Sign of Tensions Over Intellectual-Property Policies

Swiss drug company Novartis AG accused India of misrepresenting its position about the country's patent laws, in another sign of tensions between India and the international pharmaceutical industry.
The rebuke came in a July 19 letter from Novartis Chief Executive Joseph Jimenez to India's minister of commerce and industry, Anand Sharma, reviewed by The Wall Street Journal.

"During a recent visit to Washington, D.C., I learned of statements attributed to you by a member of the United States Senate and the head of PhRMA that Novartis is 'pleased' with India's [intellectual-property] laws. Let me assure you this is not the case," Mr. Jimenez wrote. PhRMA stands for Pharmaceutical Research and Manufacturers of America, a trade group.

In an Aug. 5 reply, an aide to Mr. Sharma said the minister had alluded to a different pharmaceutical company in the Washington meeting. The aide, S.R. Rao, also defended Indian law and said big drug makers such as Novartis have no reason for "disillusionment or disappointment" with India.

Category: Intellectual Properties



nidhi jain said...
November 19, 2014 at 4:06 AM

many stock brokerage companies of India Epic Research  is also advisory company in stock investment market.

Post a Comment